These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2444081)

  • 1. Heterologous desensitization of platelet adenosine (A2) responses by iloprost.
    MacDermot J; Wilkins AJ; Edwards RJ
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():479-81. PubMed ID: 2444081
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet receptor desensitization induced by elevated prostacyclin levels causes platelet-endothelial cell adhesion.
    Darius H; Binz C; Veit K; Fisch A; Meyer J
    J Am Coll Cardiol; 1995 Sep; 26(3):800-6. PubMed ID: 7543911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antiaggregatory effectiveness of PGI2 and its binding to specific platelet receptors. A comparative study.
    Jaschonek K; Renn W; Weisenberger H
    Prog Clin Biol Res; 1987; 242():13-8. PubMed ID: 3313410
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 5. The intrainfusion rebound platelet activation during continuous prostaglandin I2 infusion occurs at the receptor level.
    Sinzinger H; Steurer G; Fitscha P; Kraupp O
    Prog Clin Biol Res; 1987; 242():19-23. PubMed ID: 2444986
    [No Abstract]   [Full Text] [Related]  

  • 6. Modulation of platelet [3H] iloprost binding by cholesterol, dibucaine and pentoxifylline.
    Jaschonek K; Funck M; Muller CP; Schmidt H
    Prog Clin Biol Res; 1989; 301():321-5. PubMed ID: 2477853
    [No Abstract]   [Full Text] [Related]  

  • 7. Caffeine withdrawal: apparent heterologous sensitization to adenosine and prostacyclin actions in human platelets.
    Paul S; Kurunwune B; Biaggioni I
    J Pharmacol Exp Ther; 1993 Nov; 267(2):838-43. PubMed ID: 8246157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
    Schrör K; Löbel P; Steinhagen-Thiessen E
    Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PGI2 receptors in vasculature and platelets: 5Z-carbacyclin discriminates between them.
    Nicosia S; Oliva D; Noè MA; Corsini A; Folco GC; Fumagalli R
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():474-8. PubMed ID: 2959100
    [No Abstract]   [Full Text] [Related]  

  • 10. Investigation of selective [3H]iloprost binding sites on human platelet membranes.
    Steurer G; Jankovic B; Ettl K; Schernthaner G
    Prog Clin Biol Res; 1987; 242():25-34. PubMed ID: 2444987
    [No Abstract]   [Full Text] [Related]  

  • 11. Modulation of platelet activation by prostaglandin E2 mimics.
    Thierauch KH; Prior G
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():383-6. PubMed ID: 1705385
    [No Abstract]   [Full Text] [Related]  

  • 12. Desensitization of prostacyclin responsiveness in platelets. Apparent differences in the mechanism in vitro or in vivo.
    MacDermot J
    Biochem Pharmacol; 1986 Aug; 35(16):2645-9. PubMed ID: 2427086
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential inhibition of the platelet activation sequence: shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost).
    Pedvis LG; Wong T; Frojmovic MM
    Thromb Haemost; 1988 Apr; 59(2):323-8. PubMed ID: 2455359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The platelet rebound phenomenon during PGI2-infusion occurs at the receptor level.
    Steurer G; Fitscha P; Sinzinger H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):435-8. PubMed ID: 2465947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The putative prostacyclin receptor antagonist (FCE-22176) is a full agonist on human platelets and NCB-20 cells.
    Wilkins AJ; MacDermot J
    Eur J Pharmacol; 1986 Aug; 127(1-2):117-9. PubMed ID: 2428638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractoriness of platelets to prostaglandins after infusion in rabbits.
    Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
    J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility.
    Kerins DM; Murray R; FitzGerald GA
    Prog Hemost Thromb; 1991; 10():307-37. PubMed ID: 1848945
    [No Abstract]   [Full Text] [Related]  

  • 18. Modulation of surface expression of human platelet prostacyclin receptors by cholesterol, dibucaine and pentoxifylline.
    Funck M; Muller CP; Jaschonek K
    Thromb Res; 1988 Nov; 52(4):343-7. PubMed ID: 2462288
    [No Abstract]   [Full Text] [Related]  

  • 19. Diminished inhibition of adhesion molecule expression in prostacyclin receptor desensitized human platelets.
    Darius H; Veit K; Binz C; Fisch A; Meyer J
    Agents Actions Suppl; 1995; 45():77-83. PubMed ID: 7536385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of PGD2, PGE1, and PGI2-analogues on PGDF-release and aggregation of human gelfiltered platelets.
    Stürzebecher S; Nieuweboer B; Matthes S; Schillinger E
    Prog Clin Biol Res; 1989; 301():365-9. PubMed ID: 2477855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.